<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04388202</url>
  </required_header>
  <id_info>
    <org_study_id>LEAP-SE</org_study_id>
    <secondary_id>1R44MH123373-01</secondary_id>
    <nct_id>NCT04388202</nct_id>
  </id_info>
  <brief_title>Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram</brief_title>
  <acronym>LEAP-SE</acronym>
  <official_title>Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram (LEAP-SE): A Multicenter, Randomized, Blinded Outcome Study of EEG-guided Treatment With Sertraline Versus Escitalopram in Adults With Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alto Neuroscience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alto Neuroscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The LEAP-SE study will be conducted to validate the utility of EEG biomarkers as an aid to&#xD;
      antidepressant treatment selection in adults with MDD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LEAP-SE study is an 8-week, multicenter, randomized, blinded study to evaluate the&#xD;
      performance of EEG-based biomarkers in predicting treatment outcome. Study participants will&#xD;
      be randomized in a 1:1 ratio to receive either sertraline or escitalopram and followed for 8&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled&#xD;
  </why_stopped>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">May 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate on the 16-item patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Response rate will be calculated as the percentage of participants meeting response criteria (&gt;50% reduction from baseline QIDS-SR total score at 8-week endpoint). The QIDS-SR is a 16-item, participant-rated short form of the Inventory of Depressive Symptomatology that assesses 9 domains: sad mood, concentration, self-outlook, suicidal ideation, involvement, energy/fatigability, sleep disturbance, appetite/weight increase/decrease and psychomotor agitation/retardation. Scores range from 0 (none) to 27 (very severe). The QIDS-SR total score was used to derive the mean change from baseline to endpoint depression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage decrease in depressive symptoms on the patient-reported Quick Inventory of Depressive Symptoms (QIDS-SR) at the week 8 endpoint as a function of biomarker score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quick Inventory of Depressive Symptoms (QIDS-SR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute score decrease from baseline to the week 8 endpoint on the QIDS-SR as a function of biomarker score</measure>
    <time_frame>8 weeks</time_frame>
    <description>Quick Inventory of Depressive Symptoms (QIDS-SR)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Sertraline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sertraline 100-200 mg daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Escitalopram 10-20 mg daily for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>FDA approved antidepressant</description>
    <arm_group_label>Sertraline</arm_group_label>
    <other_name>Zoloft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram</intervention_name>
    <description>FDA approved antidepressant</description>
    <arm_group_label>Escitalopram</arm_group_label>
    <other_name>Lexapro</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, aged 22 or older at the time of informed consent.&#xD;
&#xD;
          -  Diagnosis of Major Depressive Disorder (MDD) based on the Structured Clinical&#xD;
             Interview for DSM-5 for depression.&#xD;
&#xD;
          -  Moderate or severe depression on DSM-5 depression criteria items, as assessed by a&#xD;
             score of 10 or more on the Patient Health Questionnaire (PHQ-9)&#xD;
&#xD;
          -  Has not taken either study medications (sertraline, escitalopram) in the current&#xD;
             episode&#xD;
&#xD;
          -  Has not received electroconvulsive therapy (ECT), transcranial magnetic stimulation&#xD;
             (TMS), or esketamine treatment in the current episode&#xD;
&#xD;
          -  Provision of personally signed and dated written informed consent prior to any study&#xD;
             procedures&#xD;
&#xD;
          -  Agrees to, and is eligible for all biomarker assessments (EEG, neurocognitive testing,&#xD;
             activity and sleep monitoring, genetic testing)&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Ability to complete all assessments independently&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of bipolar disorder or a psychotic disorder based on the Structured Clinical&#xD;
             Interview for DSM-5.&#xD;
&#xD;
          -  Concurrent use of antidepressants, antipsychotics or mood stabilizers&#xD;
&#xD;
          -  Use of hypnotics, anxiolytics or opiate pain medications greater than three days per&#xD;
             week and unable to reduce use to three or fewer days per week on an as needed basis&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Severe impediment to vision, hearing, comprehension, and/or hand movement that&#xD;
             interferes with study tasks&#xD;
&#xD;
          -  Active substance use that interferes with ability to consent and/or complete&#xD;
             assessments&#xD;
&#xD;
          -  Any contraindication to EEG (e.g. requiring high concentration oxygen)&#xD;
&#xD;
          -  Employees/family of employees of clinic site&#xD;
&#xD;
          -  Participation in another research study within 2 months prior to the first study visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corey Keller, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alto Neuroscience</affiliation>
  </overall_official>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 11, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>EEG</keyword>
  <keyword>Biomarker</keyword>
  <keyword>Antidepressant</keyword>
  <keyword>Sertraline</keyword>
  <keyword>Escitalopram</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

